What are the current and emerging strategies to improve low HDL-C levels?

A: Dyslipidemia is a well-known risk factor for coronary heart disease (CHD). Although decreasing low-density lipoprotein cholesterol (LDL-C) levels has long been the primary objective of the management of this disorder, emphasis has also been placed on finding new therapeutic targets as a means to further decrease cardiovascular risk, including agents that raise high-density lipoprotein cholesterol (HDL-C). Low HDL-C, which was previously defined as < 35 mg/dl but recently changed to < 40 mg/dl, is classified as a major risk factor for CHD, whereas high HDL-C (? 60 mg/dl) is beneficial and considered a negative risk factor.